New combo shows promise for rare blood cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntarily provides written informed consent (ICF) prior to any study procedures. 2. Aged 18-70 years (inclusive), regardless of sex. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Histologically confirmed extranodal NK/T-cell lymphoma (ENKTL), staged as Stage III-IV or non-nasal ENKTL (per 2016 WHO Classification of Hematopoietic and Lymphoid Tumors). 5. At least one measurable/evaluable lesion (per 2014 Lugano Classification: measurable lesion ≥1.5 cm in longest diameter + ≥1.0 cm in shortest diameter; evaluable lesion with FDG uptake higher than liver on PET/CT). 6. Treatment-naive (no prior anti-cancer therapy for ENKTL). 7. Adequate organ function: AST/ALT ≤2.5×upper limit of normal (ULN); Total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine \<1.5×ULN or creatinine clearance (CrCl, via Cockcroft-Gault formula) ≥60 mL/min. 8. Reproductive-aged females have a negative pregnancy test at screening; all participants use effective contraception during the study and for 12 months after the last dose. 9. Expected survival ≥6 months. Exclusion Criteria: 1. Complicated by hemophagocytic lymphohistiocytosis (HLH) or aggressive NK-cell leukemia. 2. Contraindication to golidocitinib, PD-1 inhibitor, or any component of the P-GEMOX regimen. 3. Lymphoma involvement of the central nervous system (CNS). 4. Major surgery (excluding diagnostic biopsy) within 4 weeks prior to study treatment initiation. 5. History of other malignant tumors (except curatively treated in situ cancers, e.g., cervical carcinoma in situ) within 5 years. 6. Uncontrolled severe comorbidities (e.g., NYHA Class II+ heart failure, unstable angina, myocardial infarction within 1 year, uncontrolled arrhythmias). 7. Active bleeding (e.g., gastrointestinal hemorrhage, cerebral hemorrhage). 8. Uncontrolled infection (requiring parenteral anti-infective therapy) within 7 days prior to study treatment. 9. Active hepatitis B/C: HBsAg+/HBcAb+ with HBV-DNA \>2500 copies/mL (or 500 IU/mL); HCV antibody+ with positive HCV-RNA. 10. HIV infection or acquired immunodeficiency syndrome (AIDS). 11. Conditions impairing drug absorption (e.g., inability to swallow tablets, malabsorption syndrome). 12. Pregnant/lactating females, or reproductive-aged participants refusing contraception. 13. Psychiatric illness precluding informed consent or study compliance. 14. Other conditions deemed unsuitable for enrollment by the investigator.